EVALI syndrome in a patient with hypersensitivity pneumonitis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Smoking electronic cigarettes, or vaping, is considered by many to be a safe alternative to smoking tobacco. It was only relatively recently that reports began to appear about the development of lung damage caused by electronic cigarettes ― EVALI syndrome. Currently, the morphological manifestations of this syndrome have not been studied sufficiently due to the small number of cases described in the literature. These facts, as well as the fact that the changes that occur are not specific, and may vary in different patients, make it difficult to diagnose the disease in a timely manner.

We have described a clinical case of death in a patient who has repeatedly received inpatient treatment for interstitial lung disease, who was admitted to the pulmonology department with signs of decompensated respiratory failure after prolonged and intensive use of electronic cigarettes. The autopsy revealed morphological signs and justified the clinical symptoms of chronic hypersensitive pneumonitis in combination with EVALI syndrome.

The article also provides a brief review of the literature on EVALI syndrome and hypersensitive pneumonitis with their diagnostic criteria. Like EVALI, hypersensitive pneumonitis is difficult to recognize and diagnose by doctors, which is often associated with low awareness, as well as the absence of pathognomonic symptoms.

Full Text

Restricted Access

About the authors

Agunik O. Asatryan

Rostov State Medical University; Regional Clinical Hospital No. 2 of the Rostov Region

Author for correspondence.
Email: god2knows2@gmail.com
ORCID iD: 0009-0009-7294-4784

MD

Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don; Rostov-on-Don

Elena A. Sinelnik

Rostov State Medical University; Regional Clinical Hospital No. 2 of the Rostov Region

Email: 127pao.ob2@mail.ru
ORCID iD: 0000-0002-2201-5065
SPIN-code: 8996-5879

MD

Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don; Rostov-on-Don

Natalia G. Nedashkovskaya

Rostov State Medical University; Regional Clinical Hospital No. 2 of the Rostov Region

Email: nenagen@mail.ru
ORCID iD: 0009-0002-6583-3241

MD

Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don; Rostov-on-Don

Artyom S. Kostryukov

Rostov State Medical University

Email: artyomkostryukov@gmail.com
ORCID iD: 0009-0003-5477-858X
Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don

Nadezda A. Barsukova

Rostov State Medical University

Email: natalibarsukova@icloud.com
ORCID iD: 0009-0008-3744-2626
Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don

Ella V. Churyukina

Rostov State Medical University; Regional Clinical Hospital No. 2 of the Rostov Region; Kuban State Medical University

Email: echuryukina@mail.ru
ORCID iD: 0000-0001-6407-6117
SPIN-code: 8220-1439

MD

Russian Federation, 29 Nachitsevanskij lane, 344022 Rostov-on-Don; Rostov-on-Don; Krasnodar

References

  1. Schier JG, Meiman JG, Layden J, et al. Severe pulmonary disease associated with electronic-cigarette-product use: Interim guidance. MMWR Morb Mortal Wkly Rep. 2019;68(36):787–790. doi: 10.15585/mmwr.mm6836e2
  2. Cecchini MJ, Mukhopadhyay S, Arrossi AV, et al. E-Cigarette or vaping product use-associated lung injury: A review for pathologists. Arch Pathol Lab Med. 2020;144(12):1490–1500. doi: 10.5858/arpa.2020-0024-RA
  3. Perrine CG, Pickens CM, Boehmer TK, et al. Characteristics of a multistate outbreak of lung injury associated with E-cigarette use, or vaping. MMWR. 2019;68(39):860–864. doi: 10.15585/mmwr.mm6839e1
  4. Winnicka L, Shenoy MA. EVALI and the pulmonary toxicity of electronic cigarettes: A review. J Gen Internal Med. 2020;35(7): 2130–2135. doi: 10.1007/s11606-020-05813-2
  5. Dicpinigaitis PV, Trachuk P, Fakier F, et al. Vaping-associated acute respiratory failure due to acute lipoid pneumonia. Lung. 2020;198(1):31–33. doi: 10.1007/s00408-019-00277-6
  6. Triantafyllou GA, Tiberio PJ, Zou RH, et al. Vaping-associated acute lung injury: A case series. Am J Respir Crit Care Med. 2019;200(11):1430–1431. doi: 10.1164/rccm.201909-1809LE
  7. Podzolkov VI, Vetluzhskaya MV, Abramova AA. Vaping and vaping-associated lung injury: A review. Ther Arch. 2023;95(7): 591–596. EDN: DZLOFU doi: 10.26442/00403660.2023.07.202293
  8. Wu D, O’Shea DF. Potential for release of pulmonary toxic ketene from vaping pyrolysis of vitamin E acetate. Proc Natl Acad Sci USA. 2020;117(12):6349–6355. doi: 10.1073/pnas.1920925117
  9. Kligerman S, Raptis C, Larsen B, et al. Radiologic, pathologic, clinical, and physiologic findings of electronic cigarette or vaping product use-associated lung injury (EVALI): Evolving knowledge and remaining questions. Radiology. 2020;294(3):491–505. doi: 10.1148/radiol.2020192585
  10. Hypersensitivity pneumonitis. Clinical recommendations. Russian Respiratory Society, 2022. 56 р. (In Russ).
  11. Henry TS, Kligerman SJ, Raptis CA, et al. Imaging findings of vaping-associated lung injury. AJR Am J Roentgenol. 2020;214(3):498–505. doi: 10.2214/AJR.19.22251
  12. Henry TS, Kanne JP, Kligerman SJ. Imaging of vaping-associated lung disease. N Engl J Med. 2019;381(15):1486–1487. doi: 10.1056/NEJMc1911995
  13. Mukhopadhyay S, Mehrad M, Dammert P, et al. Lung biopsy findings in severe pulmonary illness associated with E-cigarette use (vaping). Am J Clin Pathol. 2020;153(1):30–39. doi: 10.1093/ajcp/aqz182
  14. Butt YM, Smith ML, Tazelaar HD, et al. Pathology of vaping-associated lung injury. N Engl J Med. 2019;381(18):1780–1781. doi: 10.1056/NEJMc1913069
  15. Ghinai I, Pray IW, Navon L, et al. E-cigarette product use, or vaping, among persons with associated lung injury. MMWR. 2019;68(39):865–869. doi: 10.15585/mmwr.mm6839e2
  16. Mikhailovskiy AI, Voytekhovskiy VV, Luchnikova TA. Influence of liquids for electronic cigarettes on the human respiratory system. clinical observation of a patient with evali. Bull Physiol Pathol Respiration. 2022;(84):93–99. EDN: LIWNQC doi: 10.36604/1998-5029-2022-84-93-99
  17. Mikosz CA, Danielson M, Anderson KN, et al. Characteristics of patients experiencing re-hospitalization or death after hospital discharge in a nationwide outbreak of ecigarette, or vaping, product use-associated lung injury--United States, 2019. MMWR. 2020;68(5152):1183–1188. doi: 10.15585/mmwr.mm685152e1
  18. Blanchet MR, Israel-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and invitro. Am J Respir Crit Care Med. 2004;169(8):903–909. doi: 10.1164/rccm.200210-1154OC
  19. Nair N, Hurley M, Gates S, et al. Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes. Arch Dis Child. 2020;105(11):1114–1116. doi: 10.1136/archdischild-2019-317889
  20. Sommerfeld CG, Weiner DJ, Nowalk A, Larkin A. Hypersensitivity pneumonitis and acute respiratory distress syndrome from E-cigarette use. Pediatrics. 2018;141(6):e20163927. doi: 10.1542/peds.2016-3927

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Lung: а ― shrunken lung with gobblestone appearance of the pleura due to scarring; b ― multiple air cyst due to honeycomb change.

Download (1009KB)
3. Fig. 2. Lung (microscopy): signs of hypersensitivity pneumonitis (a, b) and EVALI (c–f): a, b ― chronic interstitial inflammation, pneumofibrosis, alveolar cysts (hematoxylin-eosin, ×200); c ― diffuse reticular pneumofibrosis and hyaline membranes (PAS reaction, ×100); d ― diffuse reticular pneumofibrosis (Malori staining, ×100); e, f ― hyaline membranes, edema and thickening of alveolar septa, type II pneumocyte hyperplasia (hematoxylin-eosin, ×200); g, h ― Masson corpuscles with mucopolysaccharides and foam cells;

Download (4MB)
4. Fig. 2. Ending. g, h ― Masson corpuscles with mucopolysaccharides and foam cells; i, j ― hemorrhages, foamy cells in the lumen of the alveoli: i ― hematoxylin-eosin; j ― Malory staining (×200).

Download (2MB)

Copyright © Pharmarus Print Media, 2024



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies